Sign In

Friday, March 22, 2019 - 8:00 am to Saturday, March 23, 2019 - 3:30 pm
Add to Calendar

Course Description / Needs Statement

The Emerging Trends Conference will provide the opportunity for attendees to learn more about and improve upon their selection of precise therapy for patients with hepatocellular carcinoma. Also, attendees will increase their knowledge regarding design, implementation and participation in HCC clinical trials with an enhanced ability to assess the efficacy of treatment using a variety of response criteria.

Program Chairs

  • Josep M. Llovet, MD, PhD, FAASLD
  • Lewis R. Roberts, MBChB, PhD, FAASLD

Location

  • The Westin Buckhead Atlanta
    Atlanta, GA

Continuing Education

  • CME – 9.00 AMA PRA Category 1 Credits™
  • MOC – 9.00 points

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7:00 am ET both days.

Registration Pricing Early Bird: On or Before February 19

  • Member $325
  • Trainee & Assoc. Members $185
  • Non-Member $540
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $235
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $775
    Any Industry (pharma/device/etc.) employee with or without medical training.

Registration Pricing: On or after February 20

  • Member $425
  • Trainee & Assoc. Members $210
  • Non-Member $640
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $260
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $875
    Any Industry (pharma/device/etc.) employee with or without medical training.

Registration Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

Cancellations received by February 19, 2019 will be eligible for a full refund.

Cancellations received between February 20 – March 5, 2019 will be subject to a $50.00 cancellation fee.

Cancellations received on or after March 6, 2019 are not eligible for a refund.

Friday, March 22 -- Session I

Session I: Overview of End-Points and New Trial Designs in Cancer
Moderators: Lewis R. Roberts, MBChB, PhD, FAASLD and Timothy Meyer, MD, PhD

  • 8:00 am – 8:05 am
    Introduction and Scope of the Emerging Topic Conference
    Lewis R. Roberts, MBChB, PhD, FAASLD and Josep M. Llovet, MD, FAASLD
  • 8:05 am – 8:25 am
    Current HCC Molecular Classification
    David Wheeler, PhD
  • 8:25 am – 8:45 am
    Clinical Trial Designs Incorporating Predictive Biomarkers
    Sumithra Mandrekar, PhD
  • 8:45 am – 9:05 am
    Design and End-point Considerations in HCC Trials
    Timothy Meyer, MD, PhD
  • 9:05 am – 9:25 am
    Summary of AASLD Guidelines on Management of HCC
    Jorge A. Marrero, MD
  • 9:25 am – 9:40 am
    Panel Discussion / Q&A
  • 9:40 am – 10:00 am
    Break

Friday, March 22 -- Session II

Session II: Design and End-Points in Trials for HCC
Moderators: Josep M. Llovet, MD, FAASLD and Riccardo Lencioni, MD

  • 10:00 am – 10:20 am
    Neo-Adjuvant and Adjuvant Trials
    Peter R. Galle, MD
  • 10:20 am – 10:40 am
    Next Steps in Intermediate Stage HCC
    Riad Salem, MD
  • 10:40 am – 11:00 am
    Advanced HCC, First, Second Line and Beyond
    Josep M. Llovet, MD, FAASLD
  • 11:00 am – 11:20 am
    Radiologic Assessment of Response
    Riccardo Lencioni, MD
  • 11:20 am – 11:40 am
    Panel Discussion / Q&A
  • 11:45 am – 1:15 pm
    Lunch and Poster Session

Friday, March 22 -- Session III

Session III: Incorporating Immune Therapies into Trial Designs
Moderators: Anthony B. El-Kouiery, MD and Mitesh Borad, MD

  • 1:15 pm – 1:35 pm
    Checkpoint Inhibitors and Related Strategies
    Anthony B. El-Kouiery, MD
  • 1:35 pm – 1:55 pm
    Oncolytic and Immunovirotherapy
    Mitesh Borad, MD
  • 1:55 pm – 2:15 pm
    Is there a Role for CAR-T and Cell Therapies in HCC?
    Tim Greten, MD
  • 2:15 pm – 2:35 pm
    Panel Discussion / Q&A
  • 2:35 pm – 2:55 pm
    Break

Friday, March 22 -- Session IV

Session IV: Emerging Topics in Trial Design
Moderators: Tim Greten, MD and Myron E. Schwartz, MD

  • 2:55 pm – 3:15 pm
    Design of Clinical Trials in the Setting of Liver Transplantation
    Myron E. Schwartz, MD
  • 3:15 pm – 3:35 pm
    Recent Results from Phase II-III Studies Testing SBRT (Stereotactic Body Radiation)
    Laura Dawson, MD, FRCPC
  • 3:35 pm – 3:55 pm
    Tumor Biopsy in Trials for Advanced HCC
    Lorenza Rimassa, MD
  • 3:55 pm – 4:15 pm
    What Really Counts: Optimizing Quality of Life
    Neehar Parikh, MD
  • 4:15 pm – 4:30 pm
    Panel Discussion / Q&A

Saturday, March 23 -- Session V

Session V: Assessing Predictions of Response and Therapies
Moderators: Richard Finn, MD and Maria Reig, MD

  • 8:00 am – 8:20 am
    Side Effect Response in Assessing Efficacy
    Maria Reig, MD
  • 8:20 am – 8:40 am
    Biomarker Response in Assessing Efficacy
    Richard Finn, MD
  • 8:40 am – 9:00 am
    Liquid Biopsy Diagnosis, Prognosis & Prediction
    Augusto Villanueva, MD, PhD
  • 9:00 am – 9:20 am
    Panel Discussion / Q&A
  • 9:20 am – 9:40 am
    Break

Saturday, March 23 -- Session VI

Session VI: Novel Concepts and Challenges
Moderators: Neehar Parikh, MD and Andrew X. Zhu, MD, PhD

  • 9:40 am – 10:00 am
    The View from Industry
    Gerold Meinhardt, MD
  • 10:00 am – 10:20 am
    Challenges in Trial Design in HCC and How to Solve Them
    Andrew X. Zhu, MD, PhD
  • 10:20 am – 10:40 am
    Panel Discussion / Q&A
  • 10:40 am – 11:00 am
    Wrap-up
    Lewis R. Roberts, MBChB, PhD, FAASLD
  • 11:00 am
    Adjourn